WASHINGTON TRUST Co Has $28,000 Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

WASHINGTON TRUST Co lessened its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 88.2% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 40 shares of the biopharmaceutical company’s stock after selling 300 shares during the period. WASHINGTON TRUST Co’s holdings in Regeneron Pharmaceuticals were worth $28,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of REGN. Trust Co. of Vermont lifted its holdings in Regeneron Pharmaceuticals by 8.3% during the third quarter. Trust Co. of Vermont now owns 157 shares of the biopharmaceutical company’s stock valued at $165,000 after purchasing an additional 12 shares during the last quarter. Nvwm LLC lifted its holdings in Regeneron Pharmaceuticals by 1.4% during the third quarter. Nvwm LLC now owns 988 shares of the biopharmaceutical company’s stock valued at $1,039,000 after purchasing an additional 14 shares during the last quarter. Moss Adams Wealth Advisors LLC lifted its holdings in Regeneron Pharmaceuticals by 3.6% during the third quarter. Moss Adams Wealth Advisors LLC now owns 434 shares of the biopharmaceutical company’s stock valued at $456,000 after purchasing an additional 15 shares during the last quarter. Westhampton Capital LLC lifted its holdings in Regeneron Pharmaceuticals by 1.7% during the third quarter. Westhampton Capital LLC now owns 893 shares of the biopharmaceutical company’s stock valued at $939,000 after purchasing an additional 15 shares during the last quarter. Finally, Howe & Rusling Inc. lifted its holdings in Regeneron Pharmaceuticals by 3.4% during the third quarter. Howe & Rusling Inc. now owns 462 shares of the biopharmaceutical company’s stock valued at $486,000 after purchasing an additional 15 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.1 %

REGN stock opened at $673.60 on Friday. The company has a market capitalization of $74.02 billion, a PE ratio of 17.60, a price-to-earnings-growth ratio of 2.38 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a one year low of $642.00 and a one year high of $1,211.20. The company’s 50 day moving average price is $706.92 and its two-hundred day moving average price is $897.42. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 4.73.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same period last year, the firm posted $11.86 earnings per share. The business’s revenue was up 10.3% compared to the same quarter last year. As a group, analysts predict that Regeneron Pharmaceuticals, Inc. will post 36.67 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.52%. The ex-dividend date of this dividend is Thursday, February 20th.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on REGN shares. Piper Sandler lowered their price target on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a report on Monday, January 27th. Robert W. Baird lowered their price target on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a report on Wednesday, February 5th. Truist Financial lowered their price target on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a report on Wednesday, January 8th. Canaccord Genuity Group downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 17th. Finally, Sanford C. Bernstein lowered their price target on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.